Cargando…
p32 is a negative regulator of p53 tetramerization and transactivation
p53 is a sequence‐specific transcription factor, and proper regulation of p53 transcriptional activity is critical for orchestrating different tumor‐suppressive mechanisms. p32 is a multifunctional protein which interacts with a large number of viral proteins and transcription factors. Here, we inve...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717765/ https://www.ncbi.nlm.nih.gov/pubmed/31293051 http://dx.doi.org/10.1002/1878-0261.12543 |
_version_ | 1783447608818139136 |
---|---|
author | Ghate, Nikhil Baban Kim, Jinman Shin, Yonghwan Situ, Alan Ulmer, Tobias S. An, Woojin |
author_facet | Ghate, Nikhil Baban Kim, Jinman Shin, Yonghwan Situ, Alan Ulmer, Tobias S. An, Woojin |
author_sort | Ghate, Nikhil Baban |
collection | PubMed |
description | p53 is a sequence‐specific transcription factor, and proper regulation of p53 transcriptional activity is critical for orchestrating different tumor‐suppressive mechanisms. p32 is a multifunctional protein which interacts with a large number of viral proteins and transcription factors. Here, we investigate the effect of p32 on p53 transactivation and identify a novel mechanism by which p32 alters the functional characteristics of p53. Specifically, p32 attenuates p53‐dependent transcription through impairment of p53 binding to its response elements on target genes. Upon p32 expression, p53 levels bound at target genes are decreased, and p53 target genes are inactivated, strongly indicating that p32 restricts p53 occupancy and function at target genes. The primary mechanism contributing to the observed action of p32 is the ability of p32 to interact with the p53 tetramerization domain and to block p53 tetramerization, which in turn enhances nuclear export and degradation of p53, leading to defective p53 transactivation. Collectively, these data establish p32 as a negative regulator of p53 function and suggest the therapeutic potential of targeting p32 for cancer treatment. |
format | Online Article Text |
id | pubmed-6717765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67177652019-09-06 p32 is a negative regulator of p53 tetramerization and transactivation Ghate, Nikhil Baban Kim, Jinman Shin, Yonghwan Situ, Alan Ulmer, Tobias S. An, Woojin Mol Oncol Research Articles p53 is a sequence‐specific transcription factor, and proper regulation of p53 transcriptional activity is critical for orchestrating different tumor‐suppressive mechanisms. p32 is a multifunctional protein which interacts with a large number of viral proteins and transcription factors. Here, we investigate the effect of p32 on p53 transactivation and identify a novel mechanism by which p32 alters the functional characteristics of p53. Specifically, p32 attenuates p53‐dependent transcription through impairment of p53 binding to its response elements on target genes. Upon p32 expression, p53 levels bound at target genes are decreased, and p53 target genes are inactivated, strongly indicating that p32 restricts p53 occupancy and function at target genes. The primary mechanism contributing to the observed action of p32 is the ability of p32 to interact with the p53 tetramerization domain and to block p53 tetramerization, which in turn enhances nuclear export and degradation of p53, leading to defective p53 transactivation. Collectively, these data establish p32 as a negative regulator of p53 function and suggest the therapeutic potential of targeting p32 for cancer treatment. John Wiley and Sons Inc. 2019-07-30 2019-09 /pmc/articles/PMC6717765/ /pubmed/31293051 http://dx.doi.org/10.1002/1878-0261.12543 Text en © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Ghate, Nikhil Baban Kim, Jinman Shin, Yonghwan Situ, Alan Ulmer, Tobias S. An, Woojin p32 is a negative regulator of p53 tetramerization and transactivation |
title | p32 is a negative regulator of p53 tetramerization and transactivation |
title_full | p32 is a negative regulator of p53 tetramerization and transactivation |
title_fullStr | p32 is a negative regulator of p53 tetramerization and transactivation |
title_full_unstemmed | p32 is a negative regulator of p53 tetramerization and transactivation |
title_short | p32 is a negative regulator of p53 tetramerization and transactivation |
title_sort | p32 is a negative regulator of p53 tetramerization and transactivation |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717765/ https://www.ncbi.nlm.nih.gov/pubmed/31293051 http://dx.doi.org/10.1002/1878-0261.12543 |
work_keys_str_mv | AT ghatenikhilbaban p32isanegativeregulatorofp53tetramerizationandtransactivation AT kimjinman p32isanegativeregulatorofp53tetramerizationandtransactivation AT shinyonghwan p32isanegativeregulatorofp53tetramerizationandtransactivation AT situalan p32isanegativeregulatorofp53tetramerizationandtransactivation AT ulmertobiass p32isanegativeregulatorofp53tetramerizationandtransactivation AT anwoojin p32isanegativeregulatorofp53tetramerizationandtransactivation |